Octreotide (SMS 201-995) in the Treatment of Metastatic Glucagonoma: Report of One Case and Review of the Literature

Abstract

We report 1 patient with a necrolytic migratory erythema, a high plasma glucagon concentration and a metastatic pancreatic endocrine tumor who has now been treated effectively for 33 months with the somatostatin analogue octreotide (SMS 201–995) (400 μg/day). The results of SMS 201–995 in the treatment of glucagonoma syndrome are reviewed.